Why NervGen?

Significant Milestones
on Track for 2023/24

This website may contain “forward-looking information” and “forward-looking statements” within the meaning of applicable Canadian and United States securities legislation. Many factors could cause NervGen’s actual results, level of activity, performance or achievements or future events or developments to differ materially from those expressed or implied by the forward-looking statements including factors set forth in the NervGen’s filings on SEDAR which can be found on www.SEDAR.com. Readers should not place undue reliance on forward-looking statements made within this website. Furthermore, NervGen has no intention and undertakes no obligation to update or revise any forward-looking statements except as required by applicable law.

Key Upcoming Value Drivers

  1. Phase 1b/2a Spinal Cord Injury (SCI) proof of concept clinical trials are underway.

  2. Preclinical data in multiple indications with unmet needs (2023/24)

  3. Next generation compound progress (2023/24)

  4. Phase1b/2a Proof-of-concept readout in chronic SCI (mid-2024)


NervGen Pharma Corp. (OTCQX: NGENF, TSX-V: NGEN) is developing a first-in-class neuroreparative drug candidate for the treatment of nervous system damage.

NervGen has initiated proof-of-concept human trials for Spinal Cord injury for its lead drug candidate, NVG-291.

The Company’s initial target indications are Spinal Cord Injury, Stroke, Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS) and Alzheimer’s disease.

In the US alone:


People living with Spinal Cord Injury,
including ~18,000 new injuries each year.

(National Spinal Cord Injury Statistical Center, 2021 Fact Sheet.)


~795,000 individuals per year suffer a stroke in the USA, 87% of which are Ischemic Stroke.

(CDC: Centers for Disease Control and Prevention)


An estimated 32,000 people are living with ALS as of 2017

(CDC: Centers for Disease Control and Prevention)

Dramatic Pre-Clinical Results

“NervGen’s platform technology is truly unique and will be of significant interest in the search for a solution to Alzheimer’s disease.”

George Perry, PhD
Current and founding Editor-in-Chief of the Journal of Alzheimer’s Disease and Semmes Distinguished University Chair in Neurobiology at the University of Texas, San Antonio Hospital



Huitt Tracey

Corporate Communications
(604) 537-2094



Nancy Thompson

Vorticom, Inc.
(212) 532-2208


Leave a Reply

Your email address will not be published. Required fields are marked *